Literature DB >> 18294328

The recovery time-course of CYP3A after induction by St John's wort administration.

Hiromitsu Imai1, Tsutomu Kotegawa, Kimiko Tsutsumi, Takuya Morimoto, Nobuoki Eshima, Shigeyuki Nakano, Kyoichi Ohashi.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: St John's wort causes the induction of CYP3A. Little is known about how long the effect remains after cessation of St John's wort. WHAT THIS STUDY ADDS: The in vivo CYP3A activity returns progressively to the basal level approximately 1 week after cessation of St John's wort administration AIMS: To examine the recovery time course of CYP3A after enzyme induction by St John's wort administration.
METHODS: The subjects were 12 healthy men, aged 20-33 years. On the first day, they received an oral dose of midazolam 5 mg without St John's wort (day -14). From the next day, they took St John's wort for 14 days. On the last day of St John's wort treatment (day 0) and 3 and 7 days after completion of St John's wort treatment (days 3 and 7), they received the same dose of midazolam. On each day, blood samples were obtained until 8 h after midazolam administration. Plasma concentrations of midazolam were measured by HPLC. Pharmacokinetic parameters of midazolam were determined using noncompartmental analysis.
RESULTS: Apparent oral clearance of midazolam was significantly increased after St John's wort administration from 65.3 +/- 8.4 l h(-1) (day -14) to 86.8 +/- 17.3 l h(-1) (day 0). It returned to the control level 7 days after the completion of St John's wort (day 7, 59.7 +/- 3.8 l h(-1)). No significant difference in the elimination half-life between the four periods of the study was observed. The changes in apparent oral clearance after St John's wort discontinuation indicated that CYP3A activity recovers from enzyme induction with an estimated half-life of 46.2 h.
CONCLUSIONS: CYP3A activity induced by St John's wort administration progressively returns to the basal level after approximately 1 week. This finding may provide useful information to avoid clinically significant interactions of St John's wort with CYP3A substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294328      PMCID: PMC2432480          DOI: 10.1111/j.1365-2125.2008.03120.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  St John's Wort: effect on CYP3A4 activity.

Authors:  C A Roby; G D Anderson; E Kantor; D A Dryer; A H Burstein
Journal:  Clin Pharmacol Ther       Date:  2000-05       Impact factor: 6.875

2.  The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.

Authors:  Z Wang; J C Gorski; M A Hamman; S M Huang; L J Lesko; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2001-10       Impact factor: 6.875

3.  Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin.

Authors:  K Sugimoto; M Ohmori; S Tsuruoka; K Nishiki; A Kawaguchi; K Harada; M Arakawa; K Sakamoto; M Masada; I Miyamori; A Fujimura
Journal:  Clin Pharmacol Ther       Date:  2001-12       Impact factor: 6.875

4.  Determining hyperforin and hypericin content in eight brands of St. John's wort.

Authors:  Gerlie C de los Reyes; Robert T Koda
Journal:  Am J Health Syst Pharm       Date:  2002-03-15       Impact factor: 2.637

Review 5.  St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature.

Authors:  J M Greeson; B Sanford; D A Monti
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

6.  In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation.

Authors:  S Takedomi; H Matsuo; K Yamano; H Ohtani; Y Sawada
Journal:  J Pharm Pharmacol       Date:  2001-05       Impact factor: 3.765

7.  Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.

Authors:  Ping He; Michael H Court; David J Greenblatt; Lisa L Von Moltke
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

8.  St John's wort for depression--an overview and meta-analysis of randomised clinical trials.

Authors:  K Linde; G Ramirez; C D Mulrow; A Pauls; W Weidenhammer; D Melchart
Journal:  BMJ       Date:  1996-08-03

9.  Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.

Authors:  M F Fromm; D Busse; H K Kroemer; M Eichelbaum
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

10.  Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.

Authors:  Toshiaki Okudaira; Tsutomu Kotegawa; Hiromitsu Imai; Kimiko Tsutsumi; Shigeyuki Nakano; Kyoichi Ohashi
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

View more
  10 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

2.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

3.  The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.

Authors:  John Davis; Grant Langdon; Gary Layton; Chew Lan Chong; Marie-Noella Ndongo; Manoli Vourvahis
Journal:  Eur J Clin Pharmacol       Date:  2012-04-22       Impact factor: 2.953

Review 4.  Interactions between herbal medicines and prescribed drugs: an updated systematic review.

Authors:  Angelo A Izzo; Edzard Ernst
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

Review 6.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

7.  The effect of St John's wort on the pharmacokinetics of docetaxel.

Authors:  Andrew K L Goey; Irma Meijerman; Hilde Rosing; Serena Marchetti; Marja Mergui-Roelvink; Marianne Keessen; Jacobus A Burgers; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 5.577

8.  The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.

Authors:  Mohamed-Eslam F Mohamed; Sheryl Trueman; Tian Feng; Alan Friedman; Ahmed A Othman
Journal:  J Clin Pharmacol       Date:  2018-11-30       Impact factor: 3.126

9.  CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function.

Authors:  Katalin Mangó; Ádám Ferenc Kiss; Ferenc Fekete; Réka Erdős; Katalin Monostory
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 10.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.